1-5 of 5
Manu Sondhi
Close
Sort by
Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2296–2298.
https://doi.org/10.1182/blood-2022-166991
Published: 2022
Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker
Journal: Blood
Blood (2019) 134 (Supplement_1): 665.
https://doi.org/10.1182/blood-2019-124716
Published: 2019
Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2932.
https://doi.org/10.1182/blood-2019-129393
Published: 2019
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019
Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 792.
https://doi.org/10.1182/blood-2018-99-113609
Published: 2018